Gregory D Leonard

Summary

Affiliation: Waterford Regional Hospital
Country: Ireland

Publications

  1. ncbi ABC transporters and inhibitors: new targets, new agents
    Gregory D Leonard
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bldg 10 Rm 12N226, 9000 Rockville Pike, Bethesda, MD 20814, USA
    Curr Opin Investig Drugs 3:1652-9. 2002
  2. ncbi Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer
    Ronan J Kelly
    Waterford Regional Hospital, Ardkeen, Waterford, Ireland
    Clin Colorectal Cancer 5:166-74. 2005
  3. ncbi Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer
    Gregory D Leonard
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889 5105, USA
    BMC Cancer 5:116. 2005
  4. ncbi A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors
    Maurice A Wright
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 11:4144-50. 2005
  5. ncbi The role of ABC transporters in clinical practice
    Gregory D Leonard
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncologist 8:411-24. 2003
  6. ncbi Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy
    Gregory D Leonard
    National Cancer Institute-Navy Medical Oncology, Bethesda, MD, USA
    Anticancer Drugs 15:733-5. 2004
  7. ncbi Ductal carcinoma in situ, complexities and challenges
    Gregory D Leonard
    Cancer Therapeutics Branch, National Cancer Institute, Bethesda, MD 20889-5105, USA
    J Natl Cancer Inst 96:906-20. 2004
  8. ncbi Cutaneous reactions to chemotherapy and their management
    Angela J Wyatt
    Department of Dermatology, New York Presbyterian Hospital, Weill Medical College, Cornell University, New York, New York, USA
    Am J Clin Dermatol 7:45-63. 2006
  9. ncbi Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases
    Gregory D Leonard
    Old School of Nursing, Waterford Regional Hospital, Waterford, Ireland
    Dis Colon Rectum 49:407-10. 2006
  10. ncbi Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma
    Gregory D Leonard
    Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:2038-48. 2005

Collaborators

Detail Information

Publications13

  1. ncbi ABC transporters and inhibitors: new targets, new agents
    Gregory D Leonard
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bldg 10 Rm 12N226, 9000 Rockville Pike, Bethesda, MD 20814, USA
    Curr Opin Investig Drugs 3:1652-9. 2002
    ..This review focuses on attempts aimed at overcoming resistancemediated by ABC transporters and evaluates the prospects for addition of new inhibitors to the anticancer armamentarium...
  2. ncbi Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer
    Ronan J Kelly
    Waterford Regional Hospital, Ardkeen, Waterford, Ireland
    Clin Colorectal Cancer 5:166-74. 2005
    ..Continued progress in the field of HAI therapy may reduce the morbidity and mortality associated with CRC, so continued research in this area should be encouraged...
  3. ncbi Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer
    Gregory D Leonard
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889 5105, USA
    BMC Cancer 5:116. 2005
    ..Oxaliplatin, an agent used in first-line therapy for metastatic colorectal cancer, causes acute and chronic neurotoxicity. This study was performed to carefully assess the incidence, type and duration of oxaliplatin neurotoxicity...
  4. ncbi A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors
    Maurice A Wright
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 11:4144-50. 2005
    ..CONCLUSIONS: Doses (mg/m(2)) of CPT-11 140/24 hours, leucovorin 500/0.5 hours and 5-FU 3,120/48 hours were well tolerated...
  5. ncbi The role of ABC transporters in clinical practice
    Gregory D Leonard
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncologist 8:411-24. 2003
    ..Further optimism is warranted with the advent of potent, nontoxic inhibitors and new treatment strategies, including the combination of new targeted therapies with therapies aimed at the prevention of drug resistance...
  6. ncbi Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy
    Gregory D Leonard
    National Cancer Institute-Navy Medical Oncology, Bethesda, MD, USA
    Anticancer Drugs 15:733-5. 2004
    ..Heightened clinical suspicion for possible oxaliplatin-induced motor neuropathies may be warranted...
  7. ncbi Ductal carcinoma in situ, complexities and challenges
    Gregory D Leonard
    Cancer Therapeutics Branch, National Cancer Institute, Bethesda, MD 20889-5105, USA
    J Natl Cancer Inst 96:906-20. 2004
    ..Ongoing and recently completed studies should provide information on outcomes in patients treated with lumpectomy alone and on the effectiveness of aromatase inhibitors as an alternative to tamoxifen...
  8. ncbi Cutaneous reactions to chemotherapy and their management
    Angela J Wyatt
    Department of Dermatology, New York Presbyterian Hospital, Weill Medical College, Cornell University, New York, New York, USA
    Am J Clin Dermatol 7:45-63. 2006
    ..Early recognition and treatment of the toxicity facilitates good symptom control, prevents treatment-related morbidity, and allows continuation of anti-cancer therapy...
  9. ncbi Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases
    Gregory D Leonard
    Old School of Nursing, Waterford Regional Hospital, Waterford, Ireland
    Dis Colon Rectum 49:407-10. 2006
    ..These patients also confirm the importance of continued investigation of fluorouracil modulating agents, which may further enhance the recent progress made with fluorouracil-based combination chemotherapy for colorectal cancer...
  10. ncbi Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma
    Gregory D Leonard
    Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:2038-48. 2005
    ..This review summarizes the current data on neoadjuvant chemotherapy, the rationale for this approach, potential complications, and future prospects...
  11. ncbi Biliary tract cancers: current concepts and controversies
    Gregory D Leonard
    Memorial Sloan-Kettering Cancer Center, Gastrointestinal Oncology Service, Department of Medicine, 1275 York Avenue, Box 324, New York, New York 10021, USA
    Expert Opin Pharmacother 6:211-23. 2005
    ..Further progress in the management of biliary tract cancer is anticipated using biological therapies and continued research is essential to discover the optimal treatment for this challenging disease...
  12. ncbi Persistent CEA elevation in a patient with psoriasis and a history of metastatic colorectal cancer with no evidence of residual tumor
    Gregory D Leonard
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dig Dis Sci 49:1652-3. 2004
  13. ncbi Hepatic arterial infusion: a treatment at the "end of an era"?
    Derek G Power
    J Clin Oncol 26:2597-8; author reply 2598-9. 2008